22,211 Shares in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Acquired by CenterBook Partners LP

CenterBook Partners LP purchased a new stake in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) during the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund purchased 22,211 shares of the biopharmaceutical company's stock, valued at approximately $745,000.

A number of other hedge funds and other institutional investors have also recently modified their holdings of XENE. GF Fund Management CO. LTD. grew its position in shares of Xenon Pharmaceuticals by 21.9% during the first quarter. GF Fund Management CO. LTD. now owns 1,952 shares of the biopharmaceutical company's stock worth $65,000 after buying an additional 351 shares in the last quarter. Natixis Advisors LLC grew its position in shares of Xenon Pharmaceuticals by 1.9% during the first quarter. Natixis Advisors LLC now owns 24,010 shares of the biopharmaceutical company's stock worth $806,000 after buying an additional 456 shares in the last quarter. Occudo Quantitative Strategies LP grew its position in shares of Xenon Pharmaceuticals by 5.8% during the fourth quarter. Occudo Quantitative Strategies LP now owns 11,441 shares of the biopharmaceutical company's stock worth $448,000 after buying an additional 630 shares in the last quarter. Geode Capital Management LLC grew its position in shares of Xenon Pharmaceuticals by 1.0% during the fourth quarter. Geode Capital Management LLC now owns 69,529 shares of the biopharmaceutical company's stock worth $2,726,000 after buying an additional 720 shares in the last quarter. Finally, Swiss National Bank grew its position in shares of Xenon Pharmaceuticals by 1.0% during the fourth quarter. Swiss National Bank now owns 126,600 shares of the biopharmaceutical company's stock worth $4,963,000 after buying an additional 1,300 shares in the last quarter. 95.45% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on XENE shares. Wall Street Zen cut Xenon Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Wednesday, May 21st. Royal Bank Of Canada reduced their price target on shares of Xenon Pharmaceuticals from $58.00 to $55.00 and set an "outperform" rating for the company in a research report on Tuesday, May 13th. HC Wainwright reissued a "buy" rating and issued a $53.00 price target on shares of Xenon Pharmaceuticals in a research report on Tuesday, May 13th. William Blair reiterated an "outperform" rating on shares of Xenon Pharmaceuticals in a research note on Monday, May 5th. Finally, Chardan Capital reiterated a "buy" rating and issued a $55.00 price objective on shares of Xenon Pharmaceuticals in a research note on Tuesday, May 13th. One equities research analyst has rated the stock with a sell rating and twelve have given a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $54.82.

Xenon Pharmaceuticals Trading Down 0.3%

Shares of XENE stock traded down $0.08 during trading hours on Monday, hitting $31.51. The company's stock had a trading volume of 150,400 shares, compared to its average volume of 642,890. The stock has a market cap of $2.42 billion, a price-to-earnings ratio of -9.74 and a beta of 1.10. The business has a fifty day moving average of $31.50 and a 200-day moving average of $34.89. Xenon Pharmaceuticals Inc. has a twelve month low of $26.74 and a twelve month high of $46.00.

Xenon Pharmaceuticals (NASDAQ:XENE - Get Free Report) last issued its quarterly earnings results on Monday, May 12th. The biopharmaceutical company reported ($0.83) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.90) by $0.07. The business had revenue of $7.50 million during the quarter, compared to analyst estimates of $1.64 million. During the same period in the previous year, the business posted ($0.62) earnings per share. On average, equities analysts expect that Xenon Pharmaceuticals Inc. will post -3.1 EPS for the current fiscal year.

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.